Medtech Advised How To Stay On Top Of EU Regulatory Reform
This article was originally published in SRA
Executive Summary
Medtech companies should start reviewing sooner rather than later which of their product portfolios will remain on the market in Europe under the new Medical Device Regulation after the legislation is adopted. The next step will be to prioritize which of these products should be brought under compliance with the MDR first, then ensure timely assessments by notified bodies.